GABA receptor antagonists are drugs that inhibit the action of GABA. In general these drugs produce stimulant and convulsant effects, and are mainly used for counteracting overdoses of sedative drugs.
Examples include bicuculline, securinine and metrazol, and the benzodiazepine GABAA receptor antagonist flumazenil.
Other agents which may have GABAA receptor antagonism include the antibiotic ciprofloxacin,[1] tranexamic acid,[2] thujone,[3] ginkgo biloba,[4] and kudzu.[5]
See also
editExternal links
edit- GABA+antagonists at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
References
edit- ^ Green, M. A.; Halliwell, R. F. (October 1997). "Selective antagonism of the GABA A receptor by ciprofloxacin and biphenylacetic acid". British Journal of Pharmacology. 122 (3): 584–590. doi:10.1038/sj.bjp.0701411. ISSN 0007-1188. PMC 1564969. PMID 9351519.
- ^ Roman Furtmüller; Michael G Schlag; Michael Berger; Rudolf Hopf; Sigismund Huck; Werner Sieghart; Heinz Redl (April 2002). "Tranexamic Acid, a Widely Used Antifibrinolytic Agent, Causes Convulsions by a γ-Aminobutyric AcidA Receptor Antagonistic Effect". Journal of Pharmacology and Experimental Therapeutics. 301 (1): 168–173. doi:10.1124/jpet.301.1.168. PMID 11907171. Retrieved 1 November 2021.
- ^ Karin M. Höld; Nilantha S. Sirisoma; Tomoko Ikeda; Toshio Narahashi; John E. Casida (April 2000). "α-Thujone (the active component of absinthe): γ-Aminobutyric acid type A receptor modulation and metabolic detoxification". PNAS. 97 (8): 3826–3831. Bibcode:2000PNAS...97.3826H. doi:10.1073/pnas.070042397. PMC 18101. PMID 10725394.
- ^ Lidija Ivic; Tristan T.J. Sands; Nathan Fishkin; Koji Nakanishi; Arnold R. Kriegstein; Kristian Strømgaard (December 2003). "Terpene Trilactones from Ginkgo biloba Are Antagonists of Cortical Glycine and GABAA Receptors". Journal of Biological Chemistry. 278 (49): 49279–49285. doi:10.1074/jbc.M304034200. PMID 14504293. Retrieved 1 November 2021.
- ^ Robert M. Swift; Elizabeth R. Aston (March 2015). "Pharmacotherapy for Alcohol Use Disorder: Current and Emerging Therapies". Harvard Review of Psychiatry. 23 (2): 122–133. doi:10.1097/HRP.0000000000000079. PMC 4790835. PMID 25747925.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |